Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.48 |
| ▸ | PPARA | Q07869 | 13/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darglitazone SCHEMBL9436449 | 1.00 | PPARG (0.48) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| Darglitazone SCHEMBL20125582 | 1.00 | PPARG (0.48) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| Darglitazone SCHEMBL674635 | 0.99 | PPARG (0.48) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9520353 | 0.93 | PPARG (0.47) | PPARGPPARACYP2C9PPARD | |
| Darglitazone SCHEMBL16554324 | 0.93 | PPARG (0.44) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9521756 | 0.90 | PPARG (0.45) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9520637 | 0.89 | PPARG (0.49) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9721264 | 0.88 | PPARG (0.45) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9721260 | 0.88 | PPARG (0.45) | PPARGPPARACYP2C9CYP3A4KCNH2 | |
| SCHEMBL9721218 | 0.87 | PPARG (0.55) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7441 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250332101-A1 | Composition | CORDEIRO MARIA FRANCESCA (GB) | 2025-10-30 | — | — | US | claimed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-09-11 | — | — | US | claimed |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD (IL) | 2025-07-10 | — | — | US | claimed |
| WO-2025136060-A1 | CULTURE MEDIUM COMPOSITION FOR TRANSDIFFERENTIATION OF MUSCLE STEM CELLS INTO ADIPOCYTES, AND METHOD FOR PRODUCING CULTURED MEAT BY USING SAME | 한화솔루션 주식회사 | 2025-06-26 | — | — | WO | claimed |
| EP-4520343-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-03-12 | — | — | EP | claimed |
| WO-2025049710-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE DISEASE TREATMENTS | ACLIPSE TWO INC. (US) | 2025-03-06 | — | — | WO | claimed |
| EP-4511030-A2 | TREATMENT OF GASTROINTESTINAL DISEASES | Aclipse Two Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | claimed |
| CN-1192683-A | Method for reducing amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus | WARNER LAMBERT CO (US) | 1998-09-09 | — | — | CN | claimed |
| EP-0859608-A1 | TREATING NIDDM WITH RXR AGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | claimed |
| EP-0851757-A2 | A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1998-07-08 | — | — | EP | claimed |
| WO-1998005331-A2 | PREVENTION OR TREATMENT OF TYPE 2 DIABETES OR CARDIOVASCULAR DISEASE WITH PPAR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-02-12 | — | — | WO | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| WO-1997018811-A1 | A METHOD OF TREATING MYOTONIC DYSTROPHY | WARNER-LAMBERT COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| WO-1997010819-A1 | TREATING NIDDM WITH RXR AGONISTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-03-27 | — | — | WO | claimed |
| WO-1997005875-A2 | A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | claimed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |